NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Race to control silent liver disease hits pause
Disease control TerminatedThis study is testing whether a drug called Aramchol can reduce liver scarring and inflammation in people with NASH, a serious fatty liver disease. The trial involves about 150 adults with confirmed NASH and some liver scarring. It compares Aramchol against a placebo to see if it…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE3 • Sponsor: Galmed Research and Development, Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New drug aims to shrink dangerous liver fat
Disease control OngoingThis study is testing whether an investigational drug called miricorilant can reduce liver fat and improve liver health in adults with NASH/MASH, a serious form of fatty liver disease. About 175 participants will receive either the drug or a placebo for 24 or 48 weeks. The main g…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC